262
Participants
Start Date
September 12, 2012
Primary Completion Date
November 8, 2017
Study Completion Date
April 12, 2022
Imatinib
Dasatinib
Local Institution - 0093, La Plata
Local Institution, Budapest
Local Institution - 0080, Ramos Mejía
Local Institution - 0099, Merksem
Local Institution - 0049, San Miguel de Tucumán
Local Institution - 0024, Linz
Local Institution - 0022, Wels
Local Institution, Yvoir
Local Institution - 0026, Innsbruck
Local Institution - 0104, Szeged
Local Institution - 0043, Graz
Local Institution, Fürstenfeld
Local Institution - 0025, Orbassano
Local Institution, Bangkok
Local Institution - 0067, Prague
Hillman Cancer Center, Pittsburgh
Local Institution - 0017, A Couruna
Local Institution - 0046, Monza
Local Institution - 0106, Brescia
Edwards Comprehensive Cancer Center, Huntington
Local Institution - 0012, Madrid
Local Institution - 0015, Las Palmas de Gran Canaria
Local Institution - 0013, Salamanca
Local Institution - 0052, Khon Kaen
Local Institution, Bologna
Local Institution, Nantes
Local Institution - 0011, Toledo
Local Institution - 0002, Cincinnati
Franciscan St. Francis Health, Indianapolis
Northern Indiana Cancer Research Consortium, Crown Point
Local Institution - 0027, Florence
Local Institution - 0055, Muang
University Of Iowa, Iowa City
Local Institution - 0005, Milwaukee
Local Institution - 0038, Vandœuvre-lès-Nancy
Local Institution - 0010, Rochester
Local Institution - 0041, Lille
Northwestern University, Evanston
Carle Cancer Center, Urbana
Local Institution, Pierre-Bénite
Local Institution, Bari
Michael E Debakey VAMC, Houston
Institute of Oncology Hematology Biomedical Research, Laredo
Local Institution - 0045, Le Chesnay
Local Institution, Napoli
University Of Southern California University Hospital, Los Angeles
Local Institution - 0078, Whittier
Local Institution - 0006, Fontana
Local Institution - 0004, Anaheim
Local Institution - 0112, San Jose
Local Institution, Catania
Local Institution - 0110, Roseville
Local Institution - 0071, Beijing
Local Institution - 0086, Beijing
Local Institution - 0094, Shenyang
Local Institution - 0084, Haerbin
Local Institution - 0076, Shanghai
Local Institution - 0073, Nanjing
Local Institution - 0077, Suzhou
Local Institution - 0101, Jinan
Local Institution - 0069, Tianjin
Local Institution - 0072, Hangzhou
Local Institution - 0070, Fuzhou
Local Institution - 0102, Wuhan
Local Institution - 0096, Wuhan
Local Institution - 0082, Guangzhou
Local Institution - 0074, Guangzhou
Local Institution - 0103, Shenzhen
Local Institution - 0075, Chengdu
Local Institution - 0088, Xi'an
Local Institution - 0009, Vallejo
Local Institution - 0089, Southington
Local Institution - 0001, Nashville
Local Institution - 0051, Buenos Aires
Local Institution - 0057, Buenos Aires
Local Institution - 0100, Corrientes
Local Institution - 0023, Vienna
Local Institution - 0065, Bruges
Local Institution - 0083, Goiânia
Local Institution, Curitiba
Local Institution - 0063, Campinas
Local Institution, Ribeirão Preto
Local Institution - 0059, São Paulo
Local Institution - 0062, Rio de Janeiro
Local Institution - 0058, Rio de Janeiro
Local Institution - 0111, Rio de Janeiro
Local Institution - 0020, Saint John
Local Institution - 0032, Brno
Local Institution, Hradec Králové
Local Institution, Olomouc
Local Institution, Prague
Local Institution - 0021, Roma
Local Institution - 0033, Rome
Local Institution - 0048, Krakow
Local Institution - 0047, Gdansk
Local Institution - 0098, Katowice
Local Institution - 0064, Warsaw
Local Institution - 0039, Seoul
Local Institution - 0050, Seoul
Local Institution - 0040, Seoul
Local Institution - 0018, L'Hospitalet Del Llobregat
Lead Sponsor
ICON Clinical Research
INDUSTRY
PPD Development, LP
INDUSTRY
Molecular MD
UNKNOWN
MultiPharma
UNKNOWN
Q2 Solutions
INDUSTRY
Donald E. Morisky
UNKNOWN
MD Anderson Symptom Inventory (MDASI-CML)
UNKNOWN
OBiS, Inc
UNKNOWN
Steering Committee
UNKNOWN
Bristol-Myers Squibb
INDUSTRY